HCPLive
Digestive Disease Week 2014

Digestive Disease Week 2014 | DDW 2014

Digestive Disease Week is "the world's largest gathering of physicians and researchers in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery."

Conference Coverages

Gastroenterologists Missing Chances to Shift to Generic Medications
Gastroenterologists Missing Chances to Shift to Generic Medications
Although most gastroenterologists feel that store-brand and branded treatments are equivalent, most continue to recommend branded products for gastroesophageal reflux disease and chronic constipation, according to two studies presented at the annual Digestive Disease Week, held from May 3 to 6 in Chicago.
Triple Regimen of Direct-acting Antivirals Achieves High Sustained Virologic Response Rates in Patients with Hepatitis C
Results from the PEARL-II study show treatment-experienced patients with hepatitis C genotype 1b achieved SVR rates of greater than 96% when treated with a combination of ABT 450 with ritonavir, co-formulated with ombitasvir and dasabuvir, without the need for ribavirin.
Promising Results for First Pharmacologic Treatment for Celiac Disease
Patients with celiac disease treated with larazotide acetate experienced improvements in GI symptoms and non-GI symptoms such as headache and fatigue, as well as significant reductions in the number of symptomatic days.
Eluxadoline Effectively Treats Diarrhea-predominant Irritable Bowel Syndrome
Patients with IBS-D in two phase II trials of eluxadoline experienced sustained improvements in abdominal pain and bowel symptoms at 26 weeks of treatment, with mild side effects.
Endoscopic L-Menthol Spray Ups Colon Polyp Detection
For patients undergoing colonoscopy, L-menthol sprayed directly onto the colonic mucosa improves the adenoma detection rate, according to a study presented at the annual Digestive Disease Week, held from May 3 to 6 in Chicago.
New Regimen Effective for HCV Genotype 1a, 1b
A new regimen shows promise for hepatitis C virus (HCV) genotype 1 infection, and sofosbuvir and ribavirin are active in HCV genotypes 2 and 3 infection, according to two studies published online May 4 in the New England Journal of Medicine. This research was published to coincide with the annual Digestive Disease Week, held from May 3 to 6 in Chicago.
Research Yielding New Insights into the Emerging Therapy of Fecal Microbiota Transplant
Fecal microbiota transplants appear safe and patients tolerate them well in trials, but the evidence isn’t there yet to establish overall benefit for treating ulcerative colitis.

Most Popular

$vacMongoViewPlus$ $vAR$